- Subscribe
- Log In More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
- Basket
- Search More
Advanced search
- Latest content
- Current issue
- Archive
- Authors
- About
- Podcasts
Advanced search
- CloseMore
Main menu
- Latest content
- Current issue
- Archive
- Authors
- About
- Podcasts
See AlsoJAMA Internal Medicine—Year in Review, 2021AAIM Principles and Recommendations for the 2021-2022 Internal Medicine Residency Interview Cycle in Response to the Continued COVID-19 PandemicHypertension Guidelines: 2021 USPSTF Recommendation, 2018 ESC/ESH, 2017 ACC/AHA, and the 2014 JNC8 guideline.Office of Dietary Supplements - Omega-3 Fatty Acids - Subscribe
- Log in More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
- BMJ Journals
You are here
- Home
- Archive
- Volume 83,Issue Suppl 1
- POS0675 DIFFERENCES IN THE CHARACTERISTICS OF D2T/NOND2T-RA PATIENTS AND FACTORS ASSOCIATED WITH D2T-RA AT B/TSDMARD START
Email alerts
Article Text
Article menu
- Article Text
- Article info
- Citation Tools
- Share
- Rapid Responses
- Article metrics
- Alerts
Scientific Abstracts
Poster View
Rheumatoid arthritis
POS0675 DIFFERENCES IN THE CHARACTERISTICS OF D2T/NOND2T-RA PATIENTS AND FACTORS ASSOCIATED WITH D2T-RA AT B/TSDMARD START
- A. Eken1,
- G. Ayan2,
- Z. Özsoy2,
- G. Sandal Uzun2,
- M. Ekici3,
- E. Ünaldi2,
- G. S. Kart-Bayram2,
- B. Firlatan2,
- B. Bulat2,
- E. Bilgin2,
- A. Akdoğan2,
- O. Karadag2,
- Ş. A. Bilgen2,
- A. I. Ertenli2,
- S. Kiraz2,
- U. Kalyoncu3,
- L. Kiliç3
- 1Hacettepe University Faculty of Medicine, Internal Medicine, Ankara, Turkey
- 2Hacettepe University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey
- 3Hacettepe University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey
Abstract
Background: Rheumatoid arthritis (RA) is a common rheumatic disease characterised by joint damage and reduced quality of life. Despite numerous treatment options, some patients do not achieve remission or low disease activity. These patients have been defined as having difficult-to-treat RA (D2T-RA) by the European Alliance of Associations for Rheumatology (EULAR) 2021[1].
Objectives: This study was conducted to determine the prevalence of ‘difficult-to-treat’ RA in our centre and the factors associated with D2T at biologic/targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD) initiation.
Methods: Patients who applied to the outpatient clinic of Hacettepe University Department of Internal Medicine, Division of Rheumatology between 1 April-30 November 2023 with a diagnosis of RA and using b/tsDMARD were included in this study. Patients fulfilling all three EULAR D2T RA criteria were accepted as D2T RA [1]. Patients were cross-sectionally divided into D2T and non-D2T based on their visit dates between the study periods.
Patients were defined as D2T-RA when they met; A: Failure of ≥2 bDMARDs/tsDMARDs (with different mechanisms of action) after treatment according to EULAR recommendations and failure of conventional synthetic DMARDs (unless contraindicated); AND B: Presence of at least one of the following: moderate or more severe disease activity (DAS28 ≥3. 2), signs and/or symptoms consistent with active disease (elevated erythrocyte sedimentation rate (ESR) for age, C-reactive protein ≥0.5), inability to reduce steroid therapy below prednisolone 7.5 mg or equivalent, and RA symptoms affecting quality of life (Health Assessment Questionnaire, HAQ ≥1.2). AND C: Management of signs and/or symptoms perceived as problematic by the rheumatologist and/or the patient (Physician Global Assessment or Patient Global Assessment VAS ≥50 or Patient Acceptable Symptom State (PASS) negative). Radiographic progression was not included in this assessment as it was not available. Demographic, clinical and treatment data were assessed at the time of b/tsDMARD initiation according to D2T status. And comorbidities were assessed for any diagnosis ever made. To understand the factors that are associated with D2T-RA at b/tsDMARD initiation, a 1:1 matched cohort for b/tsDMARD duration were created. The factors associated with D2T status on univariate analysis with significance at the 0.20 level were entered into a multivariable model. Backward elimination method was used at a significance of 0.05 level.
Results: A total of 502 patients were evaluated. Of these, 38.4% had D2T RA with a mean (SD) age of 56.7 (12.1) years and 85.6% were female. Compared to the non-D2T patients, the D2T patients had a significantly higher body mass index and tender joint counts, but no difference was observed in the treatment strategies used before thE b/ts DMARD start (Table 1). Regarding comorbidities, D2T patients had higher rates of ever made diagnosis of hypertension (90 (46.4%) vs 96 (31.1%), p=0.001) and coronary artery disease (20 (24.4%) vs 12 (11.3%), p=0.018), with no significant difference in diabetes mellitus, osteoporosis and malignancy (p >0.1 for all). When D2T patients were matched to non-D2T patients according to the b/tsdmard duration, there were 173 patients from 2 groups with a mean (SD) b/tsDMARD duration of 6.3 (7.2) years. Final model revealed, HAQ score ≥ 1 at b/tsDMARD start as a factor for D2T-RA (OR 2.08 (1.17-3.69), p= 0.01) (Table 2).
Conclusion: There are nearly 40% of patients determined as D2T in our cohort. The high rates can be attributed to the cohort characteristics as this is a b/tsDMARD cohort which required advanced treatment from the start and patients were under follow-up. HAQ score ≥ 1 at the time of b/tsDMARD start, is an independent factor associated with D2T-RA in the future.
REFERENCES: [1] Nagy G, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021;80(1):31-5.
Table 1. Demographic, clinical and therapeutic characteristics of D2T patients at b/tsDMARD initiation
- Download figure
- Open in new tab
- Download powerpoint
Table 2. Factors that are associated with being DT2 in the future when starting a b/tsDMARD (D2T RA patients, n=173, non-D2T-RA patients, n=173)
- Download figure
- Open in new tab
- Download powerpoint
Acknowledgements: NIL.
Disclosure of Interests: None declared.
- biological DMARD
- Prognostic factors
- Real-world evidence
Statistics from Altmetric.com
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
- biological DMARD
- Prognostic factors
- Real-world evidence
Read the full text or download the PDF:
Subscribe
Log in via Institution
Log in via OpenAthens
Log in using your username and password
Read the full text or download the PDF:
Subscribe
Log in via Institution
Log in via OpenAthens